中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2011, 23(1): 86-89
干扰程序性死亡分子1及其配体信号通路的免疫治疗
汪龚泽,刘朝奇*
三峡大学分子生物学研究所,宜昌 443002
摘 要: 程序性死亡分子1(programmed death-1, PD1)及其配体(programmed death ligand, PDL)属于B7家族的共刺激分子,介导免疫反应的负性调节信号,在肿瘤发生、病毒感染以及自身免疫病中都发挥了特异性的调节作用。利用PD1/PDL1信号途径调节机体的免疫应答从而达到免疫治疗的目的,该文就此展开综述。
关键词:PD1;PDL1;免疫调节;免疫治疗
 
A therapeutic strategy of targeting PD1/PDL signal pathway
WANG Gong-Ze, LIU Chao-Qi*
Institute of Molecular Biology, Three Gorges University, Yichang 443002, China
Abstract:  PD1(programmed death-1, PD1)and PDL1(programmed death ligand-1, PDL1) are members of co-stimulating molecules of B7 superfamily. PDL1 binds to PD-1, which  mainly expresses on the activated T cells, mediates the negative modulating signals. Interfering the PD1/PDL signal pathway regulates the immunological responses, which could be used as a therapeutic strategy for cancer, viral infection and auto-immune diseases. In this paper, we reviewed the current progress of the associated research.
Key words: PD1; PDL1; immuno-regulation; immunotherapy
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2992833 位访问者,欢迎!